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Background: Recent years have seen rapid and significant progress in science and implementation of programs to
prevent mother-to-child transmission of HIV. Programs that support PMTCT routinely monitor service provision but
very few have measured their effectiveness. The objective of the study was to use service data to inform HIV-free
survival among HIV exposed children that received antiretroviral drugs to prevent mother-to-child transmission
(PMTCT) of HIV. The study was conducted in two rural districts in Malawi with support from FHI 360.
Methods: A descriptive observational study of PMTCT outcomes was conducted between June 2005 and June
2009. The dataset included patient-level data of all pregnant women 1) that tested HIV-positive, 2) that were
dispensed with antiretroviral prophylaxis, and 3) whose addresses were available for home visits. The data were
matched to each woman’s corresponding antenatal clinic data from home visit registers.
Results: Out of 438 children whose home addresses were available, 33 (8%) were lost to follow-up, 35 (8%) were
alive but not tested for HIV by the time home visit was conducted, and 52 (12%) were confirmed deceased. A total
of 318 children were alive at the time of the home visit and had an HIV antibody test done at median age 15
months. The resulting estimated 24-month probability of HIV-free survival over all children was 78%. Among
children who did not receive nevirapine, the estimated 24-month probability of HIV-free survival was 61%, and
among those who did receive NVP syrup the estimate was 82%.
Conclusions: When mothers and newborns received nevirapine, the estimated 24-month probability of HIV-free
survival among children was high at 82% (CI: 54% to 99%). However this conclusion should be interpreted
cautiously 1) due to the wide confidence interval; and 2) because the confidence interval range includes 55%,
which is the natural HIV-free survival rate in the absence of a PMTCT intervention. This analysis highlighted the
need of quality data and well-structured home visits to assess PMTCT effectiveness.Background
Mother-to-child transmission of HIV (MTCT) accounts
for an estimated 1,000 pediatric HIV infections every
day, the majority of which occur in sub-Saharan Africa
[1]. In this part of the world, the combination of high
HIV prevalence, high birth rates and under-resourced
health systems have resulted in a heavy toll on children’s
health outcomes.
Recent years have seen rapid and significant progress in
science and implementation of programs to prevent
MTCT. Proven interventions for prevention of mother-to-* Correspondence: jmandala@fhi360.org
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reproduction in any medium, provided the orchild transmission (PMTCT) are available and are being
implemented globally, including resource-constrained set-
tings [2-4]. Programs that support PMTCT routinely
monitor service provision but very few have measured
their effectiveness [5,6].
Data on effectiveness of PMTCT programs are crucial
to not only gauge if programmatic and operational tar-
gets are being reached, but also to continually refine
provision of PMTCT services in order to control the
pediatric HIV epidemic.
The objective of this study was to use service data to es-
timate HIV-free survival among children born to HIV-
positive mothers that received antiretroviral (ARV) drugsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in Malawi between June 2005 and June 2009.Program description
Malawi has one of the highest HIV seroprevalence rates
among sub-Saharan countries; in 2004 a population
based survey estimated that 12.7% of adults between 15
and 49 years old were living with HIV [1,7]. In 2005,
HIV seroprevalence among pregnant women was esti-
mated to be 27% in urban areas [8]. An estimated
100,000 children below the age of 15 live with HIV and
one-fifth of the 99.1 deaths per 1,000 children under 15
are attributable to HIV [1,9]. PMTCT coverage remains
a significant problem in Malawi; in 2009, only an esti-
mated 58% of HIV-positive pregnant women with HIV
infection and 41% of HIV-exposed infants were provided
with ARVs to prevent MTCT [10].
Between 2005 and 2009, in partnership with the Min-
istry of Health of Malawi, FHI 360 supported a program
to mitigate the impact of HIV on children in Chikwawa
and Dowa, two rural districts. Chikwawa and Dowa have
an estimated HIV seroprevalence of 11% and a popula-
tion of 435,000 and 560,000 inhabitants respectively
[11,12]. A specific objective of the program was to scale
up PMTCT programs in 15 health centers (eight in
Chikwawa and seven in Dowa). FHI 360 support con-
sisted of training and mentoring on PMTCT, commod-
ities procurement, data collection, reporting and quality
assurance as well as community mobilization.
FHI 360 supported the Ministry of Health to train
and re-train all relevant health personnel on national
PMTCT guidelines and the importance that they be sys-
tematically followed. During the training, in an effort to
strengthen the follow-up component of PMTCT and im-
prove documentation during antenatal visits and home
visits, specific emphasis was given to proper record
keeping and report writing using the existing national
tools. The PMTCT program spanned the cascade of ser-
vices, including HIV counseling and testing of pregnant
women, provision of ARV prophylaxis among those
identified as HIV positive, provision of infant ARV
prophylaxis, provision of infant HIV testing, and follow-
up home visits. All HIV-positive mothers and their HIV-
exposed children were referred for comprehensive HIV
clinical care including lifelong antiretroviral treatment
(ART) as needed. At the time of implementation, single
dose nevirapine (sdNVP) was the backbone of PMTCT
programs in rural Malawi; complex ARV regimens be-
yond sdNVP were not being implemented.
PMTCT related clinical activities-such as testing and
counseling for HIV, provision of sdNVP to HIV-positive
mothers, and provision of nevirapine (NVP) syrup to the
newborn were carried out by nurses and midwives.Outside of the health centers, community health work-
ers conducted monthly home visits to HIV-positive
mothers that received ARVs and to their HIV-exposed
children between zero and 24 months postnatal. Home
visits were routine practice conducted by community
health workers. During home visits, psychosocial support,
adherence counseling for cotrimoxizole preventative ther-
apy and ARVs, and HIV care were provided. Additionally
an assessment of the HIV and living status of the infants
was conducted. For this study, HIV status was recorded
from the most recent test; there was no documentation
on the number or outcomes of HIV tests performed previ-
ously. Lastly, the health passports of the mothers were
reviewed to confirm their attendance at follow-up
appointments and make new appointments if necessary.
Health passports are individual books provided to each
client when first attending a health facility.
Data from both health facilities and community based
activities were routinely collected. Key indicators for
PMTCT were integrated into registers from antenatal
clinic (ANC) and registers from other complimentary
services such as HIV counseling and testing, family plan-
ning, and sexually transmitted infections.
At the time of program implementation, the national
policy of Malawi on HIV diagnosis included three rapid
tests: Determine HIV 1/2 for screening, Uni-Gold HIV
test for confirmation and SD Bioline HIV1/2 3.0 as a tie-
breaker. The first two tests were run in parallel until May
2008 when the national policy changed to serial testing.
The national policy recommended new HIV rapid test kits
in 2008, but by the end of the program supported by FHI
360, the change was not yet operational in rural sites.
In practice, HIV-exposed children were tested for HIV
at different ages as a result of several key challenges. First,
it was not uncommon for mothers to not return to the
health facility on their appointment date to have their
child examined and tested. Next, the follow-up home vis-
its were not always scheduled at consistent time intervals,
due to shortages of health care workers and high client
volumes. Lastly, there were a number of parents who relo-
cated due to employment-especially in Chikwawa which is
a sugarcane growing area. Large sugar estates attract
people seeking seasonal employment.Methods
Design
This is a descriptive observational study of PMTCT
activities.Site selection
The 13 PMTCT sites included in the analysis were among
the fifteen supported by FHI 360 in the Chikwawa and
Dowa districts. Two of the fifteen FHI 360-supported
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follow-up of mother-baby pairs beyond ANC.
Data collection and entry
Patient-level data collected from the ANC register
included information on all pregnant women 1) that
tested HIV-positive, 2) that were dispensed with ARV
prophylaxis, and 3) whose home visit information was
available. The data were matched to each woman’s corre-
sponding ANC data from the home visit register. For the
purpose of this study the following data were extracted
from the ANC register: 1) age of the mother at the first
ANC visit, 2) parity, 3) distance in kilometers (km) from
her house to the health center, and 4) whether the
woman’s HIV-positive status was disclosed to her partner.
From the home visit register, additional data were
extracted: 1) mother’s living status, 2) mother’s access to
HIV clinical care, 3) whether postnatal NVP was given to
the infant at birth, 4) child’s living status, 5) infant feeding
method, and 6) child’s HIV status.
The accuracy of the data collected both at health facil-
ities and during home visits was monitored throughout
the implementation of the PMTCT programs by FHI
360’s monitoring and evaluation team. These data were
double-entered into a Microsoft Excel database version
2003 (2).
Data analysis
The outcome considered for this analysis is HIV-free
survival until the age of 24 months. HIV-free survival is
defined as being alive and confirmed HIV-uninfected at
the time of home visits.
Because the exposed infant’s HIV status was first
assessed and documented between the ages of six weeks
and 24 months after birth, it was not possible to know
precisely when HIV infection occurred. For example, an
infant who was first tested for HIV at age six months and
was found to be positive could have become infected any
time between birth and six months. Similarly, an infant
who was known to have died by six months of age may
have become infected prior to death. Thus, nonparametric
methods for interval censored data [13] (similar to
Kaplan-Meier methods) were used to estimate, along with
95% confidence intervals, the cumulative probability of
HIV-free survival at 24 months postnatal.
In univariate and multivariate models, hazard ratios
were estimated, along with 95% confidence intervals,
using parametric Weibull proportional hazards models,
which account for interval censored data, to explore the
associations between HIV-free survival and 1) sex of the
child, 2) mother’s living status, 3) duration of time an in-
fant was breastfed (less than six months vs. over six
months), 4) whether the child received NVP, and 5)
whether the mother received (lifelong) ART. Dataanalysis was performed using SAS, Version 9.2 (SAS In-
stitute, Cary, NC, USA).
Ethical approval
This data review was submitted to the FHI 360′s Protec-
tion of Human Subjects Committee. It was determined
that this study does not constitute human subject re-
search as defined under DHHS regulation 45 CFR




Between June 2005 and June 2009, a total of 40,691
pregnant women were registered in FHI 360 supported
antenatal clinics; 40,139 were counseled and tested for
HIV (98.6% uptake) and 2,408 women were found to be
HIV-positive (6.0% HIV prevalence). Of those who
tested HIV positive, 1,851 were dispensed with sdNVP
(76.9% uptake of ARV prophylaxis among mothers) and
1,353 of newborns to HIV-positive mothers received
NVP syrup (56.2% uptake of infant ARV prophylaxis).
The uptake of PMTCT interventions was higher in FHI
360 supported sites than the national average. The drop-
out in number of women and their HIV-exposed neo-
nates receiving ARV is due to the low proportion (56%)
of women completing the four antenatal visits and the
low proportion (50%) of institutional delivery observed
in rural Malawi [10]. Not all pregnant women tested
HIV-positive came back to be dispensed with NVP
tablets and even fewer brought their neonates to be pro-
vided with NVP syrup.
In this analysis, 438 HIV-positive pregnant women
were registered in antenatal books, had received sdNVP,
and had received follow up home visits. These 438
patients represent 23.6% of women that tested HIV posi-
tive and were dispensed with ARVs; the remaining
(76.4%) could not be followed because their home
addresses were missing from the registers.
The mothers’ median age was 28.0 years; they lived a
median of 5 km from the antenatal clinic, and had a me-
dian parity of 3. Overall, 99% of HIV-exposed children
had ever been breastfed, 62% of those for over six
months. The profile of mothers who were lost to follow-
up (LTFU) was comparable to the profile of those who
were able to be tracked through home visits (Table 1).
As shown in Figure 1, of the 438 children whose
mothers received sdNVP and provided their addresses,
33 (8%) were considered LTFU, i.e. after delivery, com-
munity health workers could not locate the mothers or
their children despite availability of their home address
in the register. Furthermore, 35 infants (8%) were alive
but were never tested for HIV by the time home visit
was conducted and 52 (12%) were confirmed deceased.
Table 1 Profile of mothers included in the review
Among mothers not LTFU Among mothers LTFU
N Mean StdMedianMinMax N MeanStdMedianMinMax
Mothers’ age 369 27.9 5.6 28 12 44 30 28.7 5.8 28 18 41
Mothers parity 372 3.3 1.9 3 1 11 23 3.4 1.8 4 1 7
Kms to ANC* 382 7.8 9.5 5 0.1 50.0 3 2.5 3.0 1 0.5 6.0
* Distance in kilometers to the antenatal clinic.
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home visit and had an HIV antibody test conducted
prior to the time of home visit. The median age of the
children was 15 months, with a range of six weeks to
33.8 months. Of those 318 children, 274 tested negative
and 44 tested positive for HIV antibodies. Among the 44
with a positive result, 15 were tested at age 18 months
or older, and therefore confirmed to be infected with
HIV. However the HIV status of the remaining 29
infants, who were tested prior to age 18 months, could
not be definitely established per WHO guidelines on the
diagnosis of HIV in children [14]. Note that in this ana-
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Figure 1 HIV-free survival flow chart.to age 18 months were categorized as HIV-infected in
the determination of HIV-free survival.
Overall HIV-free survival
Of the 438 HIV-exposed children whose mothers
received sdNVP and provided their address, 349 were
included in the analysis. A total of 89 children were
excluded from analysis due to missing data.
The resulting estimated 24-month probability of HIV-
free survival among all children was 78%, with 95% con-
fidence interval (CI) 41% to 99%. Among children who
did not receive NVP syrup, the estimated 24-month
probability of HIV-free survival was 61% (CI: 21% to
99%), and among those who did receive NVP syrup the
estimate was 82% (CI: 54% to 99%).
Factors associated with HIV-free survival
The results from the univariate and multivariate propor-
tional hazards models for interval censored data are
shown in Table 2. Among the factors explored, only “chil-
dren who did receive NVP” was significantly associated
with HIV-free survival; the estimated hazard ratio was
2.77 (CI: 1.61 to 4.78). Being female child was associatedsitive Status: 
 antibody test 
18 mo
5
ren born to HIV+ mothers
438
ed and (information) retrieved
405
d children that tested or died
370
xposed children tested for HIV 
antibodies
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Table 2 Estimated* hazard ration (HR) for selected factors associated with HIV-free survival
Factors Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Child is female 1.54 (0.96, 2.46) 0.071 1.65 (0.99, 2.75) 0.053
Mother not alive 2.09 (0.51, 8.62) 0.309 1.04 (0.14, 7.85) 0.968
Breastfed< 6 months 0.95 (0.13, 7.02) 0.961 1.63 (0.21, 12.94) 0.642
Breastfed ≥6 months 0.79 (0.11, 5.75) 0.813 1.49 (0.19, 11.90) 0.705
Child did not receive NVP 2.76 (1.69, 4.49) < 0.001 2.77 (1.61, 4.78) < 0.001
Mother not on ART when breastfeeding 0.89 (0.55, 1.43) 0.620 0.71 (0.42, 1.21) 0.207
* From a parametric Weibull proportional hazards model.
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was borderline-HR 1.65 (CI: 0.99 to 2.75).
Discussion
This study has demonstrated the usefulness and limita-
tions of using service data to inform HIV-free survival as
a result of PMTCT programs. It measured not only the
proportion of infants that were not HIV-infected, but
also the ultimate outcome of PMTCT intervention: a liv-
ing child free of HIV infection. A key contribution of
this study has also been to describe the limitations of
analyzing service data to measure outcomes of PMTCT
programs.
Analysis of service data from the sdNVP based
PMTCT interventions in rural Malawi provides some
limited indication of reduced risk of MTCT [15,16]. In
this context of high breastfeeding rates, without any
intervention, HIV-free survival at 24 months postnatal
could be as low as 55% [17]. In our data, we estimated
the 24-month HIV-free survival probability to be 78%
overall and 82% when the infant dose of NVP was also
received. However, due to the sparseness of our data, the
confidence intervals around our estimates are very wide
and each spans 55%; thus, our data do not allow for any
firm conclusions.
At the time the program was implemented, the sdNVP
only regimen was offered in Malawi as the predominant
option for PMTCT, especially in rural areas. More recently,
Malawi-as with other Sub-Sahara African countries-is tran-
sitioning to more efficacious regimens. However, even in
the context of more efficacious regimens, our analysis to in-
form HIV free survival remains relevant; a PMTCT pro-
gram offering more complex ARV regimens still needs to
assess the outcomes of the intervention especially when ad-
herence to treatment might decrease with long term and
complex regimens.
Moreover, this analysis revealed how a “minimalist”
PMTCT approach-sdNVP only antiretroviral regimen-
results in a relatively high proportion (around 22%) of
HIV-exposed children dead or HIV-infected.
Detection of HIV infections in the study population
was essentially based on HIV antibody tests and couldnot have occurred earlier. A proportion of early deaths
could have been avoided if HIV diagnosis were estab-
lished by 12 months of age and pediatric antiretroviral
treatment initiated in a timely manner [3]. If not diag-
nosed and treated, approximately one-third and one-half
of HIV-infected infants will die before the age one year
and two years, respectively [18]. Improved coverage,
more effective ARV regimens, and early infant diagnosis
could have prevented a substantial proportion of these
HIV infections and deaths among HIV-exposed children.
This analysis has limitations. First, most of the chil-
dren, including those who tested HIV-negative, were still
exposed to HIV through breastfeeding-99% of children
had been breastfed-and this analysis did not adequately
capture the definitive HIV status of these HIV-exposed
infants.
Second, establishing diagnosis of HIV-infection requires
HIV testing at two different points in time, children were
tested only at one time [14]. Reasonable conclusions, how-
ever, may still be drawn as the HIV test in this circum-
stance was not meant for diagnosis but for surveillance.
Third, our analysis could not ascertain that all children
who were not alive had died of HIV infection; the regis-
ters used during home visits did not capture verbal aut-
opsy information.
Next, our analysis likely overestimates the numbers of
HIV infected infants. Infants who tested positive for
HIV antibodies at ≤ 18 months of age, were considered
HIV-infected in this analysis, even though conclusive
HIV infection status was unknown.
Finally, this study demonstrates the limitations of
analyzing routine service data. Despite efforts to
maintain good data quality, routine service data are
not comparable to data collected in formal research
studies with rigorous protocols for data collection
[19]. For example, two-thirds of HIV-exposed children
that received ARV prophylaxis could not be included
in the analysis because data on their mother’s address
were not registered. It is not possible to determine if
the rate of HIV-free survival among this group is
comparable to those who were followed up through
home visits. During program implementation, the
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not regularly conducted, which prevented the follow-
up of a large proportion of HIV-exposed children and
their mothers. This analysis highlights the need to
have good quality service data-from both health facil-
ities and home visits. As the quality of service data
improves, so does its ability to measure HIV-free
child survival rates.
Moreover, among the large proportion of mothers for
whom home addresses were not available, there was not
a significant difference in their age, parity, or distance
between home and the clinic. Despite that there is no
existing evidence of bias between the mothers who were
LTFU versus those who were tracked through home vis-
its, it cannot be completely ruled out.
Lastly, the study population does not represent a ran-
dom sample, therefore the results may not be
generalizable to a larger population. A greater sample
size in a representative number of sites, availability of
defined age at the time of HIV testing, as well as docu-
mentation of the number and results of previous HIV
tests would have allowed more detailed analysis and pos-
sibly firmer conclusions.Conclusion
Our analysis reports on HIV-free survival among children
born to HIV-positive mothers in rural health centers in
Malawi. It was possible to couple analysis of routine
PMTCT service data with information collected during
routine home visits to analyze PMTCT outcomes.
Among our study population, the HIV-free survival
rate of HIV-exposed children was between 61% and
82%. However, the confidence intervals around our esti-
mates are quite wide and each span 55%, the natural
HIV-free survival rate observed in the absence of any
PMTCT intervention. Therefore, this analysis does not
lead to a firm conclusion.
In order to better understand-and achieve clear statis-
tical evidence-of HIV-free survival, such service data
should be collected routinely, systematically, and in a
more representative number of sites. In addition to
quantity of data, this analysis highlighted the need to
have good quality data from health facilities and home
visits, as well as better structured home visits. We rec-
ommend that 1) mothers’ addresses are routinely col-
lected to enable follow-up, 2) testing of HIV-exposed
infants are done at specific ages (e.g. six weeks, six
months, 12 months, 18 months), 3) clinical data are sys-
tematically recorded during home visits (duration and
type of mother’s ARV regimen and age of HIV testing of
children), 4) quality control of data being collected is
ensured, and 5) a strategy to drastically reduce LTFU
among HIV-positive pregnant mothers is implemented.Competing interests
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